SR&ED for Biotech and Life Sciences Companies

Canadian biotech, pharmaceutical, and life sciences companies qualify for SR&ED credits on drug discovery, assay development, molecular biology, and clinical research — often at combined federal and provincial rates exceeding 50%.

What biotech work qualifies for SR&ED?

Any life sciences R&D work that involves genuine technological uncertainty, systematic investigation, and the pursuit of technological advancement qualifies. The SR&ED program does not require commercial success — only that the work involved genuine experimentation to resolve an uncertain technical outcome.

• Novel compound synthesis where activity or mechanism was uncertain
• Assay development, optimization, and validation for new targets
• In-vitro and in-vivo studies investigating new biological hypotheses
• Formulation development with uncertain stability or delivery profiles
• Bioprocess engineering and fermentation optimization
• Bioinformatics algorithm development for novel sequence analysis

Biotech companies building bioinformatics pipelines, genomic analysis tools, or laboratory informatics software may qualify for SR&ED on those software work streams separately from wet-lab activities. The same three-part eligibility test applies; see our guide on SR&ED for software companies for how technical uncertainty is assessed in a software context.

Drug discovery, assay development, and preclinical research

Preclinical work is among the most SR&ED-eligible activity in Canadian life sciences. Lead identification, hit-to-lead optimization, and IND-enabling studies all typically involve substantial technological uncertainty. The key is documentation: what was the hypothesis, what was tried, what failed, and what was learned. Lab notebooks and study reports are the primary evidence.

Assay development qualifies when the assay itself required novel technical work — not when you’re running an established assay to generate data. The distinction matters: running a validated ELISA is routine; developing a new binding assay for an unstudied target is SR&ED.

CRO fees and third-party subcontractor costs

Fees paid to Canadian CROs for SR&ED work are fully eligible. Payments to non-Canadian CROs are eligible only if the work could not be reasonably performed in Canada and meets CRA’s 80% subcontractor rule (or uses Form T1263 for full inclusion). Your agreement with the CRO must specify the SR&ED nature of the work, and your company must retain the rights to results.

Documentation requirements for life sciences SR&ED

CRA expects contemporaneous records — documents created at the time of the work, not reconstructed later. For biotech SR&ED, the most important records are:

• Lab notebooks (electronic or bound), dated and signed by the researcher
• Study protocols, amendments, and study reports
• In-process data, dose-response curves, assay readouts, and failure analyses
• Reformulation logs documenting what was changed and why
• Time allocation records for each researcher by SR&ED project
• Financial records linking material purchases and contractor invoices to specific projects

Provincial stacking: maximizing federal and Quebec credits

Most provinces offer R&D incentives that stack with the federal SR&ED ITC. Quebec’s credit is the most significant for life sciences — up to 30% on eligible salaries for small CCPCs, on top of the federal 35%. British Columbia, Ontario, and other provinces also offer credits. Your accountant should claim all applicable provincial incentives alongside the federal T661 filing.

For medical device companies and biotech companies in Quebec, the combined federal-provincial benefit on eligible salaries can exceed 50%. This is among the most favourable R&D tax environments in the world for early-stage life sciences.